Sales driver: Bayer share: New study data could increase sales potential of Bayers Xarelto | message

—The Voyager Pad phase III clinical trial investigated whether the drug also works in patients with leg circulation problems who have had to undergo surgery.

When Xarelto was given in combination with acetylsalicylic acid (ASA), the risk of certain serious consequences decreased compared to treatment with ASA alone, as Bayer announced in Berlin on Saturday. It is about circulatory disorders and breaks in the legs, amputations, heart attacks and strokes.

On Sunday, Bayer also presented data from the Pronomos phase IIIb study, according to which Xarelto significantly reduces the risk of severe venous thromboembolism after small orthopedic surgery. Compared to enoxaparin, this is around 75 percent lower.

The data was also presented at the US Cardiology Congress ACC. You could open up the possibility of expanding the Xarelto label – the funds could then be used more widely. Xarelto has long been one of the most important sales drivers in the pharmaceutical business of Leverkusen and is approved in several indications for adults, such as deep venous thrombosis, the prevention of strokes in patients with atrial fibrillation and pulmonary embolism. In 2019, Bayer generated sales of 4.1 billion euros with Xarelto.

The drug is marketed outside of the US by Bayer, on the US market itself through a subsidiary of the US company Johnson & Johnson. However, patent protection for Xarelto is imminent in a few years, and competitors could then put copycat products on the market.

/ mis / fba / he

BERLIN (dpa-AFX)

advertising